Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

12,732 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Real-world outcomes of avelumab plus axitinib in patients with advanced renal cell carcinoma in Japan: long-term follow-up from the J-DART2 retrospective study.
Kato T, Furukawa J, Hinata N, Ueda K, Hara I, Hongo F, Mizuno R, Okamoto T, Okuno H, Ito T, Kajita M, Oya M, Tomita Y, Shinohara N, Eto M, Uemura H. Kato T, et al. Int J Clin Oncol. 2025 Jan;30(1):99-109. doi: 10.1007/s10147-024-02618-9. Epub 2024 Nov 16. Int J Clin Oncol. 2025. PMID: 39549218 Free PMC article.
Results of weekday-on and weekend-off administration schedule of sunitinib therapy for advanced renal cell carcinoma.
Kawashima A, Uemura M, Kato T, Ujike T, Nagahara A, Fujita K, Imamura R, Yamanaka Y, Tomiyama E, Tanigawa G, Miyagawa Y, Yoshioka T, Miyake O, Nonomura N. Kawashima A, et al. Among authors: kato t. Int J Clin Oncol. 2019 Jan;24(1):78-86. doi: 10.1007/s10147-018-1332-1. Epub 2018 Aug 9. Int J Clin Oncol. 2019. PMID: 30094693 Free PMC article.
Expression of Nectin-4 and PD-L1 in Upper Tract Urothelial Carcinoma.
Tomiyama E, Fujita K, Rodriguez Pena MDC, Taheri D, Banno E, Kato T, Hatano K, Kawashima A, Ujike T, Uemura M, Takao T, Yamaguchi S, Fushimi H, Yoshimura K, Uemura H, Netto GJ, Nonomura N. Tomiyama E, et al. Among authors: kato t. Int J Mol Sci. 2020 Jul 29;21(15):5390. doi: 10.3390/ijms21155390. Int J Mol Sci. 2020. PMID: 32751328 Free PMC article.
The prognostic impact of immune-related adverse events in metastatic renal cell carcinoma patients treated with nivolumab: a real-world multi-institutional retrospective study.
Kato T, Nagahara A, Kawamura N, Nakata W, Soda T, Matsuzaki K, Hatano K, Kawashima A, Ujike T, Imamura R, Nishimura K, Takada S, Tsujihata M, Yamaguchi S, Takao T, Nishimura K, Nonomura N, Uemura M. Kato T, et al. Int J Clin Oncol. 2021 May;26(5):954-961. doi: 10.1007/s10147-021-01872-5. Epub 2021 Jan 20. Int J Clin Oncol. 2021. PMID: 33471290
Novel diagnostic model for bone metastases in renal cell carcinoma patients based on bone scintigraphy analyzed by computer-aided diagnosis software and bone turnover markers.
Ujike T, Uemura M, Kato T, Hatano K, Kawashima A, Nagahara A, Fujita K, Imamura R, Nonomura N. Ujike T, et al. Among authors: kato t. Int J Clin Oncol. 2022 Apr;27(4):774-780. doi: 10.1007/s10147-021-02107-3. Epub 2022 Feb 4. Int J Clin Oncol. 2022. PMID: 35119579 Free PMC article.
Trop-2 in Upper Tract Urothelial Carcinoma.
Tomiyama E, Fujita K, Nakano K, Kuwahara K, Minami T, Kato T, Hatano K, Kawashima A, Uemura M, Takao T, Fushimi H, Katayama K, Imoto S, Yoshimura K, Imamura R, Uemura H, Nonomura N. Tomiyama E, et al. Among authors: kato t. Curr Oncol. 2022 May 30;29(6):3911-3921. doi: 10.3390/curroncol29060312. Curr Oncol. 2022. PMID: 35735421 Free PMC article.
Real-world efficacy and safety of nivolumab plus ipilimumab in untreated metastatic renal cell carcinoma, and the impact of previous nephrectomy on clinical outcome: Japanese multi-institutional retrospective study.
Kato T, Fujita K, Minami T, Nagahara A, Hyashi Y, Nakata W, Matsuzaki K, Nakano K, Hatano K, Kawashima A, Imamura R, Takada S, Nishimura K, Tsujihata M, Takao T, Nakai Y, Nakayama M, Nishimura K, Uemura M, Uemura H, Nonomura N. Kato T, et al. Int J Clin Oncol. 2022 Oct;27(10):1596-1604. doi: 10.1007/s10147-022-02215-8. Epub 2022 Jul 13. Int J Clin Oncol. 2022. PMID: 35831538
The Association of Tumor Immune Microenvironment of the Primary Lesion with Time to Metastasis in Patients with Renal Cell Carcinoma: A Retrospective Analysis.
Fujita K, Kimura G, Tsuzuki T, Kato T, Banno E, Kazama A, Yamashita R, Matsushita Y, Ishii D, Fukawa T, Nakagawa Y, Fukuyama T, Sano F, Kondo Y, Uemura H. Fujita K, et al. Among authors: kato t. Cancers (Basel). 2022 Oct 26;14(21):5258. doi: 10.3390/cancers14215258. Cancers (Basel). 2022. PMID: 36358675 Free PMC article.
IMAGENE trial: multicenter, proof-of-concept, phase II study evaluating the efficacy and safety of combination therapy of niraparib with PD-1 inhibitor in solid cancer patients with homologous recombination repair genes mutation.
Kato T, Matsubara N, Shiota M, Eto M, Osawa T, Abe T, Shinohara N, Yasumizu Y, Tanaka N, Oya M, Nishimoto K, Hayashi T, Nakayama M, Kojima T, Namikawa K, Fujisawa T, Okano S, Hida E, Nakamura Y, Bando H, Yoshino T, Nonomura N. Kato T, et al. BMC Cancer. 2022 Dec 9;22(1):1292. doi: 10.1186/s12885-022-10398-6. BMC Cancer. 2022. PMID: 36494792 Free PMC article. Clinical Trial.
A comparative study on nivolumab and axitinib as secondary treatment in patients with metastatic renal cell carcinoma: A multi-institutional retrospective study in Japan.
Kato T, Yumiba S, Nakata W, Nakano K, Nagahara A, Matsuzaki K, Hayashi Y, Hatano K, Kawashima A, Takao T, Nishimura K, Nakai Y, Nakayama M, Nishimura K, Takada S, Tsujihata M, Uemura M, Nonomura N, Imamura R. Kato T, et al. Int J Urol. 2023 Sep;30(9):723-729. doi: 10.1111/iju.15130. Epub 2022 Dec 28. Int J Urol. 2023. PMID: 36578154
12,732 results
You have reached the last available page of results. Please see the User Guide for more information.